Next Generation Sequencing Global market - Forecast to 2022

Publishing Date : November, 2016
Report Code : HCBT 0100
Price:
Single license $4,950
Site license $6,750
Global license $9,000


A decade has gone, since the first human genome has been sequenced and sequencing technology has come a long way from the time of introduction as Next Generation Sequencing (NGS) has revolutionized the way the human genomes are being sequenced now a days. The time and cost to sequence has tremendously reduced since the first human genome was sequenced, which took a decade time and around $3 billion. But now a human genome can be sequenced at a cost of just $1,000 in one to two days. In the last five years, the sequencing cost has rapidly reduced and this is supposed to have a huge impact on the NGS market in the coming years.

The global Next Generation Sequencing market is expected to grow at a double digit CAGR to reach $14,722.5 million by 2022. The NGS market is classified based on products, technology, end users, application and geography. The global NGS products are further divided into instruments, services and workflow products. The NGS technology is segmented into reversible terminator sequencing, ion semiconductor sequencing, sequencing by ligation, single molecule real time sequencing (SMRT), and others. The NGS application market is segmented in two different ways, one by sequencing process and the other by field of application. The NGS application market by type of sequencing process has been categorized into genomics, epigenomics, transriptomics, and others. By field of application, the market has been divided into diagnostics, drug discovery and development, biomarker discovery, agriculture and animal research, and others. The NGS market by end users is divided into academic research laboratories, hospitals and clinics, biotech and pharmaceuticals, and other end users, which include nonprofit organizations and commercial labs.

Further, the NGS market is separated by geographical regions into North America, Europe, Asia-pacific and Rest of the World.

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKE AWAYS
    • 2.2     REPORT DESCRIPTION
    • 2.3     MARKETS COVERED
    • 2.4     STAKEHOLDERS
    • 2.5     RESEARCH METHODOLOGY
      • 2.5.1     MARKET SIZE ESTIMATION
      • 2.5.2     MARKET CRACKDOWN AND DATA TRIANGULATION
      • 2.5.3     SECONDARY SOURCES
      • 2.5.4     PRIMARY SOURCES
      • 2.5.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.5.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.5.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     REDUCED COST AND HIGH SPEED
        • 3.3.1.2     INCREASED USAGE IN CLINICAL DIAGNOSIS
        • 3.3.1.3     SWITCH TO NGS FROM MICROARRAY TECHNOLOGY
        • 3.3.1.4     NEW & EMERGING APPLICATIONS OF NGS TECHNOLOGY
        • 3.3.1.5     GROWTH OF PERSONALIZED MEDICINE
        • 3.3.1.6     INCREASED MEDICAL SPENDING
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     COMPLICATIONS IN NGS DATA STORAGE
        • 3.3.2.2     STANDARDIZATION OF NGS FOR DIAGNOSTIC APPLICATION
        • 3.3.2.3     GRANTS AND FUNDING FOR NGS INFRASTRUCTURE
        • 3.3.2.4     LACK OF SKILLED LABOR
        • 3.3.2.5     HUGE AND COMPLEX NGS DATA INTERPRETATION
        • 3.3.2.6     ETHICAL AND LEGAL ISSUES TO NGS
    • 3.4     TECHNOLOGICAL ADVANCEMENTS
      • 3.4.1     NANOPORE SEQUENCING BASED TECHNIQUES
        • 3.4.1.1     ELECTRONIC BIOSCIENCES NANOPORE SEQUENCING
        • 3.4.1.2     ROCHE’S NANOTAG CHEMISTRY
        • 3.4.1.3     NABSYS NANOPORE SEQUENCER
        • 3.4.1.4     STRATOS NANOPORE SEQUENCING
      • 3.4.2     ELECTRONIC OPTICA’S MAD-LEEM
      • 3.4.3     GENAPSYS GENIUS
      • 3.4.4     LASERGEN’S LIGHTENING TERMINATOR CHEMISTRY
      • 3.4.5     QUANTUMDX HANDHELD SEQUENCING INSTRUMENT
      • 3.4.6     ZS GENETICS ADF-STEM
    • 3.5     REGULATORY AFFAIRS
      • 3.5.1     U.S.
      • 3.5.2     EUROPE
      • 3.5.3     CHINA
      • 3.5.4     INDIA
      • 3.5.5     JAPAN
    • 3.6     PORTER’S FIVE FORCE ANALYSIS
      • 3.6.1     THREAT OF NEW ENTRANTS
      • 3.6.2     THREAT OF SUBSTITUTES
      • 3.6.3     BARGAINING POWER OF SUPPLIERS
      • 3.6.4     BARGAINING POWER OF BUYERS
      • 3.6.5     COMPETITIVE RIVALRY
    • 3.7     PATENT TRENDS
    • 3.8     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
  • 4     NEXT GENERATION SEQUENCING GLOBAL MARKET, BY TECHNOLOGY
    • 4.1     INTRODUCTION
    • 4.2     REVERSIBLE TERMINATOR SEQUENCING
    • 4.3     ION SEMICODUCTOR SEQUENCING
    • 4.4     SEQUENCING BY LIGATION
    • 4.5     SINGLE MOLECULE REAL-TIME SEQUENCING (SMRT)
    • 4.6     OTHERS
  • 5     NGS GLOBAL MARKET, BY PRODUCT TYPE
    • 5.1     INTRODUCTION
      • 5.1.1     INSTRUMENTS
      • 5.1.2     SERVICES
        • 5.1.2.1     DATA ANALYSIS SERVICES
        • 5.1.2.2     SEQUENCING SERVICES
      • 5.1.3     WORKFLOW PRODUCTS
  • 6     NEXT-GENERATION SEQUENCING GLOBAL MARKET, BY APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     NGS GLOBAL APPLICATION MARKET, BY PROCESS
      • 6.2.1     GENOMICS
        • 6.2.1.1     WHOLE GENOME SEQUENCING
        • 6.2.1.2     EXOME SEQUENCING
        • 6.2.1.3     TARGET RESEQUENCING
        • 6.2.1.4     DE NOVO SEQUENCING
      • 6.2.2     EPIGENOMICS
        • 6.2.2.1     CHIP SEQUENCING
        • 6.2.2.2     METHYL SEQUENCING
      • 6.2.3     TRANSCRIPTOMICS
        • 6.2.3.1     RNA SEQUENCING
      • 6.2.4     OTHERS
    • 6.3     NGS GLOBAL APPLICATION MARKET, BY FIELD TYPE
      • 6.3.1     DIAGNOSTICS
        • 6.3.1.1     CANCER DIAGNOSTICS
        • 6.3.1.2     INFECTIOUS DISEASE DIAGNOSTICS
        • 6.3.1.3     GENETIC SCREENING
        • 6.3.1.4     TRANSPLANTATION DIAGNOSTICS
      • 6.3.2     DRUG DISCOVERY AND DEVELOPMENT
      • 6.3.3     BIOMARKER DISCOVERY
      • 6.3.4     AGRICULTURE AND ANIMAL RESEARCH
      • 6.3.5     OTHER APPLICATIONS
  • 7     NEXT-GENERATION SEQUENCING GLOBAL MARKET, BY END USERS
    • 7.1     INTRODUCTION
    • 7.2     ACADEMIC RESEARCH
    • 7.3     HOSPITALS AND CLINICS
    • 7.4     BIOTECH/PHARMACEUTICALS
    • 7.5     OTHER END USERS
  • 8     NEXT-GENERATION SEQUENCING GLOBAL MARKET, BY REGION
    • 8.1     INTRODUCTION
    • 8.2     NORTH AMERICA
      • 8.2.1     U.S.
      • 8.2.2     OTHERS
    • 8.3     EUROPE
      • 8.3.1     UNITED KINGDOM (U.K.)
      • 8.3.2     GERMANY
      • 8.3.3     SPAIN
      • 8.3.4     OTHERS
    • 8.4     ASIA-PACIFIC
      • 8.4.1     CHINA
      • 8.4.2     SOUTH KOREA
      • 8.4.3     AUSTRALIA
      • 8.4.4     OTHERS
    • 8.5     REST OF THE WORLD
      • 8.5.1     BRAZIL
      • 8.5.2     SOUTH AFRICA
      • 8.5.3     MIDDLE EAST
      • 8.5.4     OTHERS
  • 9     COMPANY DEVELOPMENTS
    • 9.1     INTRODUCTION
      • 9.1.1     NEW PRODUCT LAUNCH AS A MAJOR GROWTH STRATEGY OF NGS MARKET PLAYERS
    • 9.2     NEW PRODUCT LAUNCH
    • 9.3     AGREEMENTS, PARTNERSHIPS & COLLABORATIONS
    • 9.4     ACQUISITIONS
    • 9.5     OTHER DEVELOPMENTS
  • 10     MAJOR PLAYER PROFILES
    • 10.1     AGILENT TECHNOLOGIES, INC.
      • 10.1.1     OVERVIEW
      • 10.1.2     FINANCIALS
      • 10.1.3     PRODUCT PORTFOLIO
      • 10.1.4     KEY DEVELOPMENTS
      • 10.1.5     BUSINESS STRATEGY
      • 10.1.6     SWOT ANALYSIS
    • 10.2     BGI (BEIJING GENOMICS INSTITUTE)
      • 10.2.1     OVERVIEW
      • 10.2.2     FINANCIALS
      • 10.2.3     PRODUCT PORTFOLIO
      • 10.2.4     KEY DEVELOPMENTS
      • 10.2.5     BUSINESS STRATEGY
      • 10.2.6     SWOT ANALYSIS
    • 10.3     DNASTAR, INC.
      • 10.3.1     OVERVIEW
      • 10.3.2     FINANCIALS
      • 10.3.3     PRODUCT PORTFOLIO
      • 10.3.4     KEY DEVELOPMENTS
      • 10.3.5     BUSINESS STRATEGY
      • 10.3.6     SWOT ANALYSIS
    • 10.4     EUROFIN GENOMICS
      • 10.4.1     OVERVIEW
      • 10.4.2     FINANCIALS
      • 10.4.3     PRODUCT PORTFOLIO
      • 10.4.4     KEY DEVELOPMENTS
      • 10.4.5     BUSINESS STRATEGY
      • 10.4.6     SWOT ANALYSIS
    • 10.5     ILLUMINA, INC.
      • 10.5.1     OVERVIEW
      • 10.5.2     FINANCIALS
      • 10.5.3     PRODUCT PORTFOLIO
      • 10.5.4     KEY DEVELOPMENTS
      • 10.5.5     BUSINESS STRATEGY
      • 10.5.6     SWOT ANALYSIS
    • 10.6     OXFORD NANOPORE TECHNOLOGIES LTD
      • 10.6.1     OVERVIEW
      • 10.6.2     FINANCIALS
      • 10.6.3     PRODUCT PORTFOLIO
      • 10.6.4     KEY DEVELOPMENTS
      • 10.6.5     BUSINESS STRATEGY
      • 10.6.6     SWOT ANALYSIS
    • 10.7     PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
      • 10.7.1     OVERVIEW
      • 10.7.2     FINANCIALS
      • 10.7.3     PRODUCT PORTFOLIO
      • 10.7.4     KEY DEVELOPMENTS
      • 10.7.5     BUSINESS STRATEGY
      • 10.7.6     SWOT ANALYSIS
    • 10.8     QIAGEN N.V.
      • 10.8.1     OVERVIEW
      • 10.8.2     FINANCIALS
      • 10.8.3     PRODUCT PORTFOLIO
      • 10.8.4     KEY DEVELOPMENTS
      • 10.8.5     BUSINESS STRATEGY
      • 10.8.6     SWOT ANALYSIS
    • 10.9     ROCHE HOLDINGS AG
      • 10.9.1     OVERVIEW
      • 10.9.2     FINANCIALS
      • 10.9.3     PRODUCT PORTFOLIO
      • 10.9.4     KEY DEVELOPMENTS
      • 10.9.5     BUSINESS STRATEGY
      • 10.9.6     SWOT ANALYSIS
    • 10.10     THERMO FISHER SCIENTIFIC, INC.
      • 10.10.1     OVERVIEW
      • 10.10.2     FINANCIALS
      • 10.10.3     PRODUCT PORTFOLIO
      • 10.10.4     KEY DEVELOPMENTS
      • 10.10.5     BUSINESS STRATEGY
      • 10.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     NGS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 2     NGS GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
      • TABLE 3     NGS GLOBAL MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
      • TABLE 4     NGS GLOBAL MARKET REVENUE, BASED ON PROCESS OF APPLICATION, (2014-2022) ($MN)
      • TABLE 5     NGS GLOBAL MARKET REVENUE, BASED ON FIELD OF APPLICATION, (2014-2022) ($MN)
      • TABLE 6     NGS GLOBAL MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
      • TABLE 7     NGS GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
      • TABLE 8     REVERSIBLE TERMINATOR SEQUENCING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 9     ION SEMICONDUCTOR SEQUENCING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 10     SEQUENCING BY LIGATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 11     SINGLE MOLECULE REAL-TIME SEQUENCING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 12     OTHERS SEQUENCING TECHNOLOGY GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 13     NGS GLOBAL MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
      • TABLE 14     NGS INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 15     NGS SERVICES GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 16     NGS SERVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 17     DATA ANALYSIS SERVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 18     SEQUENCING SERVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 19     WORKFLOW PRODUCTS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 20     NGS GLOBAL MARKET REVENUE, BASED ON PROCESS OF APPLICATION, (2014-2022) ($MN)
      • TABLE 21     GENOMICS APPLICATION GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 22     GENOMICS APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 23     WHOLE GENOME SEQUENCING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 24     EXOME SEQUENCING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 25     TARGETED SEQUENCING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 26     DE NOVO SEQUENCING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 27     EPIGENOMICS APPLICATION GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 28     EPIGENOMICS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 29     CHIP SEQUENCING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 30     METHYL SEQUENCING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 31     RNA SEQUENCING (TRANSCRIPTOMICS) GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 32     OTHERS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 33     NGS GLOBAL MARKET REVENUE, BASED ON FIELD OF APPLICATION, (2014-2022) ($MN)
      • TABLE 34     DIAGNOSTICS APPLICATION GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 35     DIAGNOSTICS APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 36     CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 37     INFECTIOUS DISEASE DIAGNOSTICS APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 38     GENETIC SCREENING APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 39     TRANSPLANTATION DIAGNOSTICS APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 40     DRUG DISCOVERY AND DEVELOPMENT APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 41     BIOMARKER DISCOVERY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 42     AGRICULTURE AND ANIMAL RESEARCH APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 43     OTHERS APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 44     NGS GLOBAL MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
      • TABLE 45     ACADEMIC RESEARCH GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 46     HOSPITALS AND CLINICS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 47     BIOTECH/PHARMACEUTICALS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 48     OTHERS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 49     NGS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 50     NORTH AMERICAN NGS MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
      • TABLE 51     NORTH AMERICAN NGS MARKET REVENUE, BY COUNTRY, (2014-2022) ($MN)
      • TABLE 52     NORTH AMERICAN NGS MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
      • TABLE 53     NORTH AMERICAN NGS SERVICE MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 54     NORTH AMERICAN NGS MARKET REVENUE, BASED ON PROCESS OF APPLICATION, (2014-2022) ($MN)
      • TABLE 55     NORTH AMERICAN NGS GENOMICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 56     NORTH AMERICAN NGS EPIGENOMICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 57     NORTH AMERICAN NGS APPLICATION MARKET REVENUE, BASED ON FIELD OF APPLICATION, (2014-2022) ($MN)
      • TABLE 58     NORTH AMERICAN NGS DIAGNOSTICS APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 59     NORTH AMERICAN NGS END-USERS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 60     EUROPEAN NGS MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
      • TABLE 61     EUROPEAN NGS MARKET REVENUE, BY COUNTRY, (2014-2022) ($MN)
      • TABLE 62     EUROPEAN NGS MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
      • TABLE 63     EUROPEAN NGS SERVICE MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 64     EUROPEAN NGS MARKET REVENUE, BASED ON PROCESS OF APPLICATION, (2014-2022) ($MN)
      • TABLE 65     EUROPEAN NGS GENOMICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 66     EUROPEAN NGS EPIGENOMICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 67     EUROPEAN NGS MARKET REVENUE, BASED ON FIELD OF APPLICATION, (2014-2022) ($MN)
      • TABLE 68     EUROPEAN NGS DIAGNOSTICS APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 69     EUROPEAN NGS END-USERS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 70     ASIA-PACIFIC NGS MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
      • TABLE 71     ASIA-PACIFIC NGS MARKET REVENUE, BY COUNTRY, (2014-2022) ($MN)
      • TABLE 72     ASIA-PACIFIC NGS MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
      • TABLE 73     ASIA-PACIFIC NGS SERVICE MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 74     ASIA-PACIFIC NGS MARKET REVENUE, BASED ON PROCESS OF APPLICATION (2014-2022) ($MN)
      • TABLE 75     ASIA-PACIFIC NGS GENOMICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 76     ASIA-PACIFIC NGS EPIGENOMICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 77     ASIA-PACIFIC NGS APPLICATION MARKET REVENUE, BASED ON FIELD OF APPLICATION, (2014-2022) ($MN)
      • TABLE 78     ASIA-PACIFIC NGS DIAGNOSTICS APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 79     ASIA-PACIFIC NGS MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
      • TABLE 80     REST OF THE WORLD NGS MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
      • TABLE 81     REST OF THE WORLD NGS MARKET REVENUE, BY COUNTRY, (2014-2022) ($MN)
      • TABLE 82     REST OF THE WORLD NGS MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
      • TABLE 83     REST OF THE WORLD NGS SERVICE MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 84     REST OF THE WORLD NGS MARKET REVENUE, BASED ON PROCESS OF APPLICATION, (2014-2022) ($MN)
      • TABLE 85     REST OF THE WORLD NGS GENOMICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 86     REST OF THE WORLD NGS EPIGENOMICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 87     REST OF THE WORLD NGS APPLICATION MARKET REVENUE, BASED ON FIELD OF APPLICATION, (2014-2022) ($MN)
      • TABLE 88     REST OF THEWORLD NGS DIAGNOSTICS APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 89     REST OF THE WORLD NGS MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
      • TABLE 90     NEW PRODUCT LAUNCH (2014-2016)
      • TABLE 91     AGREEMENTS, PARTNERSHIP & COLLABOARTION (2014-2016)
      • TABLE 92     ACQUISITIONS (2014-2016)
      • TABLE 93     OTHER DEVELOPMENTS (2014-2016)
      • TABLE 94     AGILENT TECHNOLOGIES INC: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 95     AGILENT TECHNOLOGIES INC.: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 96     AGILENT TECHNOLOGIES INC.: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 97     ILLUMINA INC: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
      • TABLE 98     ILLUMINA INC: TOTAL REVENUE, BY SEGMENTS, (2014 -2016) ($MN)
      • TABLE 99     ILLUMINA INC, : TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 100     PACIFIC BIOSCIENCES: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
      • TABLE 101     PACIFIC BIOSCIENCES: TOTAL REVENUE, BY SEGMENT, (2014-2016) ($MN)
      • TABLE 102     PACIFIC BIOSCIENCES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 103     QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 104     QIAGEN N.V.: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 105     QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 106     ROCHE HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 107     ROCHE HOLDINGS AG: TOTAL REVENUE BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 108     ROCHE HOLDINGS AG: DIAGNOSTICS REVENUE BY TYPES, (2014-2016) ($MN)
      • TABLE 109     ROCHE HOLDINGS AG: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 110     THERMOFISHER SCIENTIFIC, INC.: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 111     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 112     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)

      LIST OF FIGURES

      • FIGURE 1     NGS GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
      • FIGURE 2     NGS GLOBAL MARKET: RESEARCH METHODOLOGY
      • FIGURE 3     NGS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     NGS GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     NGS GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
      • FIGURE 6     NGS GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     NGS GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 9     NGS GLOBAL MARKET: PATENT FILING BY MAJOR PLAYERS (2011-2016)
      • FIGURE 10     NGS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS (2015) (%)
      • FIGURE 11     NGS GLOBAL MARKET SHARE, BY TECHNOLOGY, (2015 V’S 2022) (%)
      • FIGURE 12     NGS PLATFORM INSTALLATION BASE (2015) (%)
      • FIGURE 13     NGS TECHNOLOGY GLOBAL MARKET SCENARIO, (2014-2022) CAGR (%)
      • FIGURE 14     NGS GLOBAL MARKET SHARE, BY PRODUCTS, (2015 V’S 2022) (%)
      • FIGURE 15     NGS GLOBAL MARKET SHARE, BASED ON PROCESS OF APPLICATION, (2015) (%)
      • FIGURE 16     GENOMICS APPLICATION GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
      • FIGURE 17     EPIGENOMICS GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
      • FIGURE 18     NGS GLOBAL MARKET SHARE, BASED ON FIELD OF APPLICATION, (2015) (%)
      • FIGURE 19     DIAGNOSTICS APPLICATION GLOBAL MARKET SHARE, BY TYPE, (2015 V’S 2022) (%)
      • FIGURE 20     NGS GLOBAL MARKET REVENUE, BY END USERS, (2015 V’S 2022) ($MN)
      • FIGURE 21     NGS END-USERS MARKET SHARE, BASED ON NUMBER OF INSTRUMENTS INSTALLED (2015) (%)
      • FIGURE 22     NGS GLOBAL MARKET REVENUE, BY REGION, (2014 - 2022) ($MN) CAGR (%)
      • FIGURE 23     NORTH AMERICAN NGS GLOBAL MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 24     NORTH AMERICAN NGS GLOBAL MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 25     U.S. NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 26     U.S. NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 27     OTHERS NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 28     OTHERS NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 29     EUROPEAN NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 30     EUROPEAN NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 31     U.K. NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 32     U.K. NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 33     GERMANY NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 34     GERMANY NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 35     SPAIN NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 36     SPAIN NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 37     OTHERS NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 38     OTHERS NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 39     ASIA-PACIFIC NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 40     ASIA-PACIFIC NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 41     CHINA NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 42     CHINA NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 43     SOUTH KOREA NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 44     SOUTH KOREA NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 45     AUSTRALIA NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 46     AUSTRALIA NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 47     OTHERS NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 48     OTHERS NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 49     REST OF THE WORLD NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 50     REST OF THE WORLD NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 51     BRAZIL NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 52     BRAZIL NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 53     SOUTH AFRICA NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 54     SOUTH AFRICA NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 55     MIDDLE EAST NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 56     MIDDLE EAST NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 57     OTHERS NGS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & END-USERS, (2015 V’S 2022) ($MN)
      • FIGURE 58     OTHERS NGS MARKET REVENUE, BASED ON PROCESS & FIELD OF APPLICATION, (2015 V’S 2022) ($MN)
      • FIGURE 59     KEY GROWTH STRATEGIES (2014-2016)
      • FIGURE 60     SWOT: AGILENT TECHNOLOGIES, INC.
      • FIGURE 61     SWOT: BGI (BEIJING GENOMICS INSTITUTE)
      • FIGURE 62     SWOT: DNASTAR, INC.
      • FIGURE 63     SWOT: EUROFIN GENOMICS
      • FIGURE 64     SWOT: ILLUMINA, INC.
      • FIGURE 65     SWOT: OXFORD NANOPORE TECHNOLOGIES LTD
      • FIGURE 66     SWOT: PACIFIC BIOSCIENCES
      • FIGURE 67     SWOT: QIAGEN N.V.
      • FIGURE 68     SWOT: ROCHE HOLDINGS
      • FIGURE 69     SWOT: THERMO FISHER SCIENTIFIC

      LIST OF COMPANIES MENTIONED IN REPORT

      • 1     10X GENOMICS
      • 2     ADAPTIVE BIOTECHNOLOGIES CORPORATION
      • 3     AGILENT TECHNOLOGIES
      • 4     AMOY DIAGNOSTICS CO
      • 5     ARCHERDX
      • 6     ASURAGEN
      • 7     BGI
      • 8     BIOMATTERS LTD
      • 9     BIOMERIEUX
      • 10     CANCER GENETICS, INC.
      • 11     CAREDX, INC.
      • 12     DANAHER CORPORATION
      • 13     DIRECT GENOMICS
      • 14     DNA ELECTRONICS
      • 15     DNASTAR, INC.
      • 16     DNAVISION SA
      • 17     ELECTRON OPTICA
      • 18     ELECTRONIC BIOSCIENCES
      • 19     EUROFINS SCIENTIFIC
      • 20     FLOWJO LLC
      • 21     GENAPSYS,INC.
      • 22     GENEWIZ
      • 23     GENOMATIX SOFTWARE GMBH
      • 24     IGENOMIX
      • 25     ILLUMINA, INC.
      • 26     INVICTA
      • 27     MACROGEN
      • 28     NABSYS
      • 29     NOBLEGEN
      • 30     NOVOGENE
      • 31     OXFORD NANOPORE TECHNOLOGIES
      • 32     PACIFIC BIOSCIENCES
      • 33     QIAGEN N.V.
      • 34     QUANTUMDX
      • 35     REAL TIME GENOMICS
      • 36     ROCHE HOLDINGS
      • 37     SEQOMICS
      • 38     SERACARE LIFE SCIENCES
      • 39     STRAND LIFESCIENCES PVT LTD
      • 40     STRATOS GENOMICS
      • 41     THERMO FISHER SCIENTIFIC, INC.
      • 42     TOMA BIOSCIENCES
      • 43     TWO PORE GUYS, INC.
      • 44     VELA DIAGNOSTICS
      • 45     VERITAS GENETICS
      • 46     WAFERGEN BIOSYSTEMS
      • 47     ZS GENETICS